Coronavirus guidance by subject
Midlands and Lancashire Commissioning Support Unit
The list of resources will be updated as new material becomes available so please check back regularly for updates.
Latest
- Cold chain management for COVID-19 vaccines (SPS)
- Handling and administration guidance common across vaccines (SPS)
- Information and guidance specific to Pfizer-BioNTech vaccine (SPS)
- Information and guidance specific to AstraZeneca vaccine (SPS)
- Information and guidance specific to Moderna vaccine (SPS)
Content
Therapeutic areas
Prescribing guidance
Operational guidance
Regional and national
Professional and regulatory
Independent and patient advocacy
Therapeutic areas
Anti-infective
- Coronavirus - COVID 19 (CKS)
- COVID-19 rapid guideline: managing COVID-19 (NICE NG191)
- COVID-19 rapid guideline: Vitamin D (NICE NG187)
- Dexamethasone in the treatment of COVID-19: COVID-19 Therapeutic Alert (MHRA)
- Notifiable diseases and causative organisms: how to report (PHE)
- Symptom Management Drug Therapy Options for COVID-19 in Primary Care (NHS North West)
Blood and blood-forming organs
- COVID 19 rapid evidence summary: Anakinra for COVID-19 associated secondary haemophagocytic lymphohistiocytosis [ES26] (NICE)
- COVID-19 updates (British Society for Haematology)
- Vitamin B12 replacement (MLCSU)
Cardiovascular system
- Coronavirus (COVID-19) and high blood pressure medication (MHRA)
- COVID-19 Clinicians Resource Hub (British Cardiovascular Society)
- COVID-19 rapid evidence summary: angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in people with or at risk of COVID-19 [ES24] (NICE)
Endocrine system
Gastro-intestinal system
- COVID-19 updates (British Society of Gastroenterology)
- COVID-19 rapid guideline:gastrointestinal and liver conditions treated with drugs affecting the immune response [NICE NG172]
Genito-urinary system
Musculoskeletal system
- Acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 (NICE, ES23)
- COVID-19: guidance for rheumatologists (British Society for Rheumatology)
- COVID-19 rapid evidence summary: Long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19 [ES25] (NICE)
- COVID-19 rapid guideline: rheumatological, autoimmune, inflammatory and metabolic bone disorders (NICE)
Nervous system
- COVID-19 guidance and advice (Association of British Neurologists)
- Depot antipsychotic injections: Administration during COVID-19 in stable adult patients (MLCSU)
- Lithium for stable adult patients: monitoring guidance. (MLCSU)
- Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (MHRA)
Respiratory system
- Community-based care of patients with chronic obstructive pulmonary disease (COPD) (NICE, NG168)
- Respiratory inhalers (BTS)
- COVID-19 rapid guideline: interstitial lung disease (NICE NG 177)
- Covid-19 rapid guideline: managing COVID-19 (NICE NG191)
- Covid-19 rapid guideline: managing the long-term effects of COVID-19 (NICE NG188)
- Using oxygen in care homes during Covid-19 (SPS)
Skin
- Advice for Dermatology HCPs during Covid-19 pandemic (British Association of Dermatologists)
- COVID-19 rapid guideline: dermatological conditions treated with drugs affecting the immune response (NICE NG 169)
Vaccines
- Cold chain management for COVID-19 vaccines (SPS)
- Handling and administration guidance common across vaccines (SPS)
- Information and guidance specific to Pfizer-BioNTech vaccine (SPS)
- Information and guidance specific to AstraZeneca vaccine (SPS)
- Information and guidance specific to Moderna vaccine (SPS)
Prescribing guidance
Controlled drugs and drug dependence
Prescribing in children
Prescribing in palliative care
- Collated list of resources for COVID-19 in palliative care (palliativedrugs.com)
- COVID-19 End of Life Anticipatory Care Plan – supporting information for Medicines Optimisation Teams (NHS North West)
- COVID-19 Primary Care Symptom Management Drug Therapy Options (NHS North West)
Prescribing in renal impairment
- Coronavirus (COVID-19) guidance for patients with kidney disease (Kidney care UK)
- COVID-19 rapid guideline: chronic kidney disease (NICE NG176)
Operational guidance
Care homes
- Bulk Prescribing for Care Homes: A Guide for Care Home Teams (NHS North West)
- Care Home and Hospice Homely Remedy Guidance during COVID-19 (NHS North West)
- Care homes’ safe access and use of medicines: guidance, templates and flowcharts (NHS North West)
- Care home support - locality template (NHS North West)
- Coronavirus (COVID-19): admission and care of people in care homes (GOV.UK)
- Coronavirus (COVID-19): support for care homes (DHSC)
- COVID-19 End of Life Anticipatory Care Plan – supporting information for Medicines Optimisation Teams (NHS North West)
- COVID-19 response: Identifying a clinical lead for all care homes (NHSEI)
- Medication Acquisition for Covid-19 symptom control in Care Homes with Nursing and Hospices (NHS North West)
- Medication Acquisition Guidance during COVID-19 for Care Homes without Nursing (NHS North West)
- Prescribers obtaining Covid19 medicines for symptom control and treatment: guidance and templates (NHS North West)
- Reuse of Medicines in Northwest Care Homes during the COVID-19 Pandemic: Guidance and Resources (NHS North West)
- Coronavirus (COVID-19): reuse of medicines in a care home or hospice (NHSEI)
- Working in care homes during COVID-19 (RPS)
Community pharmacy
- COVID-19 practical guidance and FAQs (RPS)
- Ethical, professional decision making in the COVID-19 Pandemic (RPS)
- Guidance for Manufacturers Specials licence holders on ‘packing down’ medicines during the coronavirus (COVID-19) outbreak (MHRA)
- Pandemic delivery service (PSNC)
- Primary care pharmacy during the COVID pandemic (Primary Care Pharmacy Association)
- Q&A: Coronavirus (GPhC)
- Volunteers Guidance (RPS)
Finance
- Clinical Negligence Scheme for Coronavirus (NHS Resolution > Claims management)
- Revised arrangements for NHS contracting and payment during the COVID-19 pandemic (NHSEI > Finance)
General practice
- Updates and guidance for general practice (NHSEI)
- Clinical guidance for healthcare professionals on maintaining immunisation programmes during COVID-19 (PHE)
- COVID-19 (British Medical Association)
- Notifiable diseases and causative organisms: how to report (PHE)
- Primary care pharmacy during the COVID pandemic (Primary Care Pharmacy Association)
- Principles of safe video consulting in general practice during COVID-19 (NHSEI)
- Shielded patients list: guidance for General Practice (NHS Digital)
Workforce
- Advice regarding NHS volunteers relating to COVID-19 (NHSEI)
- Community Pharmacy Volunteers Guidance (RPS)
- Coronavirus guidance for clinicians and NHS managers (NHSEI)
- COVID-19 Supporting Guidance for prescribers working within COVID hubs and Medicine Conveyance with GP bags (NHS North West)
- Organisational Prescribing Code and EPS Guide for Primary Care (NHS North West)
- Ramadan rapid review (British Islamic Medical Association)
- Risks Assessment and Considerations – for setting up COVID-19 Hubs (NHS North West)
- Stay at home: guidance for households with possible coronavirus (COVID-19) infection (PHE)
Other resources
- Analytical Collaboration for COVID-19 (MLCSU The Strategy Unit, MLCSU)
- Coronavirus (COVID-19) hub (The BMJ)
- Coronavirus (COVID-19) (SPS)
- COVID-19 Supporting Guidance for prescribers working within COVID hubs and Medicine Conveyance with GP bags (NHS North West)
- MHRA regulatory flexibilities resulting from coronavirus (COVID-19)
- Organisational Prescribing Code and EPS Guide for Primary Care (NHS North West)
- Second phase of NHS response to COVID-19: Letter from Sir Simon Stevens and Amanda Pritchard (NHSEI)
- Specialty-specific guidance on clinical care and treatment for COVID-19 (Royal College of Physicians)
- Stay at home: guidance for households with possible coronavirus (COVID-19) infection (PHE)